Why Small, Cash-Strapped Companies Should Lean Into DCTs

Deciding where to allocate funds can be a tricky endeavor for most any company, but it’s particularly burdensome for small companies. In a recent conversation on Clinical Leader Live, “Hard-Earned Lessons From Clinical Trial Implementations,” Elevar Therapeutics’ Jennifer Lee explained why these companies might want to take the leap into decentralized trials.